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Abstract 
 
Introduction: Nevirapine (NVP) is used in combination antiretroviral treatment especially for 
pregnant HIV infected women. NVP has been shown to be inferior and more toxic than other 
similar drugs, but continues to be used in developing countries due to cost. 
Aim: This study aimed to determine the prevalence of NVP toxicity and associated factors 
among 478 pregnant women from three public health facilities in inner city Johannesburg. 
Materials and methods: We employed a cross-sectional retrospective record review study 
design to analyse the records of 478 pregnant women in the above mentioned public health 
facilities.  Variables including demographic (age, weight, gestational age) and clinical (CD4 cell 
count, WHO HIV clinical stage, prior ART experience) characteristics were extracted and the 
association between these characteristics and the development of toxicity post NVP exposure 
was explored.  
Results: The study found that approximately nine out of ten women (89.5%) were ART naïve at 
the time of NVP initiation. When compared with ART naïve women, ART experienced women 
had a slightly higher mean CD4 cell count, however, for both groups of women, mean CD4 cell 
count was less than 250 cells/mm
3
. Overall, 85.1% of women had a CD4 cell count less than 250 
cells/mm
3
. More than half (55.3%) of the women were in the third trimester of pregnancy and the 
majority (82%) classified as WHO HIV clinical stage one. At least one adverse event was 
reported in 63 (13.2%) women. Mild skin rash was the most prevalent adverse event, occurring 
in 9.6% of women. Hepatotoxicity occurred in 5.3% of women and severe skin rash occurred in 
1.5% of women. Almost 85% of adverse events occurred in women with CD4 cell counts <250 
cells/mm
3
. WHO HIV clinical stage II and IV were significantly associated with the overall 
development of toxicity (ρ <0.01). 
Conclusions: Whilst the overall prevalence of mild and severe skin rash in this sample was less 
than that demonstrated in earlier studies, a higher overall prevalence of hepatotoxicity was 
found. When compared with ART naïve women, ART experienced women were found to have a 
higher prevalence of mild skin rash. Hepatotoxicity and severe skin rash only occurred in ART 
naïve women. In this sample, CD4 cell count ≥250 cells/mm3 was not associated with the 
development of NVP adverse events. 
Recommendations: Our findings support the continued use of NVP as part of combination ART 
regimens in women of African descent. In contrast with previously published data, our study 
showed a significant association between WHO HIV clinical stage and NVP toxicity, our study 
also included relatively few women with higher CD4 cell counts. Further research including 
predominantly healthy HIV infected pregnant African women as well as women with higher 
CD4 cell counts is required in order to fully explore the association between these variables and  
the development of NVP post-exposure toxicity.  
 
